Koninklijke Philips (NYSE:PHG) Sees Unusually-High Trading Volume

Koninklijke Philips (NYSE:PHG) shares saw an uptick in trading volume on Tuesday . 1,099,348 shares traded hands during mid-day trading, a decline of 3% from the previous session’s volume of 1,128,186 shares.The stock last traded at $26.88 and had previously closed at $26.71.

Analyst Ratings Changes

PHG has been the topic of several research reports. BNP Paribas lowered shares of Koninklijke Philips from an “outperform” rating to an “underperform” rating in a research note on Wednesday, February 7th. JPMorgan Chase & Co. upgraded shares of Koninklijke Philips from an “underweight” rating to a “neutral” rating in a report on Tuesday. StockNews.com raised shares of Koninklijke Philips from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. Finally, UBS Group raised shares of Koninklijke Philips from a “sell” rating to a “neutral” rating in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Koninklijke Philips presently has an average rating of “Hold” and an average price target of $19.00.

Koninklijke Philips Stock Performance

The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.78 and a current ratio of 1.20. The firm’s 50-day moving average price is $20.56 and its two-hundred day moving average price is $20.99. The firm has a market capitalization of $24.91 billion, a price-to-earnings ratio of -46.86, a price-to-earnings-growth ratio of 1.09 and a beta of 0.88.

Koninklijke Philips (NYSE:PHG) last announced its earnings results on Monday, January 29th. The technology company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. Koninklijke Philips had a negative net margin of 2.53% and a positive return on equity of 14.17%. The company had revenue of $5.45 billion during the quarter, compared to the consensus estimate of $5.47 billion. Sell-side analysts predict that Koninklijke Philips will post 1.53 earnings per share for the current year.

Institutional Investors Weigh In On Koninklijke Philips

Institutional investors and hedge funds have recently modified their holdings of the business. Cambridge Investment Research Advisors Inc. boosted its holdings in Koninklijke Philips by 3.2% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 22,616 shares of the technology company’s stock worth $451,000 after purchasing an additional 696 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its position in Koninklijke Philips by 19.4% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 12,679 shares of the technology company’s stock worth $253,000 after acquiring an additional 2,059 shares in the last quarter. Bank of New York Mellon Corp raised its position in Koninklijke Philips by 21.9% during the third quarter. Bank of New York Mellon Corp now owns 114,019 shares of the technology company’s stock worth $2,274,000 after acquiring an additional 20,499 shares in the last quarter. Advisor Partners II LLC bought a new stake in Koninklijke Philips during the third quarter worth $252,000. Finally, Assetmark Inc. raised its position in Koninklijke Philips by 1.1% during the third quarter. Assetmark Inc. now owns 99,435 shares of the technology company’s stock worth $1,983,000 after acquiring an additional 1,068 shares in the last quarter. 13.67% of the stock is owned by institutional investors.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.